Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $3.83T · View financials
Decision snapshot: ROIV stock price vs GOOGL: inconclusive — current versus $0.11 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GOOGL's multiple
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Live quote
Live quote
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · GOOGL FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 9.31x · EV / EBITDA 20.81x
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ROIVANT SCIENCES LTD. · implied price per share
Bear
$4.51
Base
$5.30
Bull
$6.10
Alphabet Inc. · implied price per share
Bear
$113.84
Base
$133.93
Bull
$154.02
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.10x
0.12x
Net debt / EBITDA
Leverage against operating earnings
32.78x
-0.42x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$126.84B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
MICROSOFT CORP
ROIV vs MSFT
AMAZON COM INC
ROIV vs AMZN
Meta Platforms, Inc.
ROIV vs META
Apple Inc.
ROIV vs AAPL
NVIDIA CORP
ROIV vs NVDA
$442.59M
$51.08B
Edwyn research
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ROIV can rapidly restore positive growth and materially improve profitability from its current negative margin profile, then the only defensible stance is to wait for a much lower entry point because the current price is far above GOOGL-implied valuation range and unsupported by fundamentals.
ROIV trades at a stark premium versus GOOGL-based valuation output, with an implied price of $0.12 versus a current price of $35.13, implying -99.6% downside. The gap is driven by extremely high revenue and EBITDA multiples for ROIV relative to GOOGL, despite ROIV’s much smaller revenue base and materially weaker profitability.
Supporting Metrics
